DCN: BSI-COA-0038 v.6.2



_	Effective Date:	8-Aug-2024	8-Aug-2027	: Date of Next Review
	Prepared By:	Carissa Albert	BSI-COA-0038 v.6.1	: Supersedes
	QA/QC Approval:	Jaron Hughes	Wayne Talamonti	: Management Approval
	Reason for Revision:	See Revision History in MasterControl		

CERTIFICATE OF ANALYSIS

POTASSIUM BROMIDE

BIO ACTIVE GRADE / KBRO-2220-05

LOT#: KBRO-E05-0825-0069

KBr & F.W. 119.00 g/mol & CAS#: 7758-02-3

Manufacturing Date: 08/20/25 Retest Date: 08/31/27 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 09/27/25 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Meets or exceeds USP and EP Specifications

TES	ST	SPECIFICATION	TEST RESULT		
Acidity or Alkalinity		Passes Test	Passes Test		
Appearance of Solution		Clear and Colorless	Clear and Colorless		
Assay		98.5 – 100.5%	99.7%		
Bromates		Passes Test	Passes Test		
Heavy Metals		10 ppm max.	< 10 ppm		
Identification	A	Passes Test	Passes Test		
Identification	В	Passes Test	Passes Test		
Iodides		Passes Test	Passes Test		
Limit of Chlorine		0.6% max.	< 0.6%		
Limit of Iron		20 ppm max.	< 20 ppm		
Loss on Drying		1.0% max.	0.2%		
Magnesium and Alka	line Earth-Metals	0.02% max.	< 0.02%		
Sulfates		0.01% max.	< 0.01%		
Trace Metals	Arsenic (As)	5 ppm max.	< 0.45 ppm		
	Copper (Cu)	5 ppm max.	< 3.0 ppm		
	Iron (Fe)	5 ppm max.	< 3.0 ppm		
	Lead (Pb)	5 ppm max.	< 3.0 ppm		

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: BSI-ATM-0014

DCN: BSI-COA-0038 v.6.2

<u>CAUTION STATEMENT:</u> For manufacturing, processing, or repacking.

CAUTION STATEMENT: Rx only.

INTENDED USE: Material represented by this Certificate of Analysis is suitable for use as a non-Sterile Active Pharmaceutical Ingredient manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product, or Household Item.

STATEMENT: Meets the chemical testing specifications of the current edition of the European Pharmacopoeia.

OVI STATEMENT: Based on the manufacturing process and the controlled handling, storage and analysis of this product, this product complies with the requirements and specifications listed in the current USP method <467> Tables 1, 2, 3, or 4.

Prepared by: And Mall	_Date: _	9/30/25	_Job Title: _	QA Tech III
Reviewed by: Am Hugh	Date:	9/30/25	Job Title:	QA Supervisor